Weekly Recap: Phase 3 CagriSema efficacy and FDA decision due Q4
Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) surged after Phase 3 REDEFINE showed CagriSema 2.4 mg drove ~25% mean weight loss, boosting hopes ahead of an FDA decision…
DO
By Daniel Okafor · Regulatory Correspondent
Oct 26 01:00 ETSource: TradingView
From the source
Read at tradingview.comWeekly Recap: Phase 3 CagriSema efficacy and FDA decision due Q4
Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) surged after Phase 3 REDEFINE showed CagriSema 2.4 mg drove ~25% mean weight loss, boosting hopes ahead of an FDA decision due Q4, even as competition from Eli Lilly, patent timelines, mixed analyst reactions and regional uptake questions temper outlooks.
